118546-61-5

Basic information

• Product Name: 1-Benzyl-4-methanesulfonyl-piperazine
• Synonyms: 1-(methylsulfonyl)-4-(phenylmethyl)Piperazine;1-Benzyl-4-methanesulfonyl-piperazine
• CAS NO: 118546-61-5
• Molecular Formula: C12H18N2O2S
• Molecular Weight: 254.352
• Mol File: 118546-61-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 158 °C
• Boiling Point: 374.5 °C at 760 mmHg
• Flash Point: 180.3 °C
• Appearance: Gray power
• Density: 1.25 g/cm³
• Vapor Pressure: 8.32E-06mmHg at 25°C
• Refractive Index: 1.597
• PKA: 5.93±0.10(Predicted)
• CAS DataBase Reference: 1-Benzyl-4-methanesulfonyl-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-methanesulfonyl-piperazine(118546-61-5)
• EPA Substance Registry System: 1-Benzyl-4-methanesulfonyl-piperazine(118546-61-5)

Safety Data

• Hazardous Substances Data: 118546-61-5(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-methanesulfonyl-piperazine is a chemical compound which belongs to the class of synthetic organic compounds known as benzylpiperazines. It is often used in the field of medicinal chemistry for its pharmacological properties and is the base structure for a number of therapeutic agents. The chemical structure of 1-Benzyl-4-methanesulfonyl-piperazine includes a piperazine ring, which is a key part of many pharmaceuticals due to its versatility and flexibility. The benzyl group and the methanesulfonyl group attached to the piperazine ring both contribute to the physical and chemical properties of this compound, and can alter its biological activity.

InChI:InChI=1/C12H18N2O2S/c1-17(15,16)14-9-7-13(8-10-14)11-12-5-3-2-4-6-12/h2-6H,7-11H2,1H3

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 124-63-0 methanesulfonyl chloride 

Relevant articles and documents

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

One-Pot synthesis of sulfonamides from primary and secondary amine derived sulfonate salts using cyanuric chloride

A convenient, mild and efficient one-pot synthesis of new sulfonamides is described. The reaction of primary or secondary amine derived sulfonate salts in the presence of cyanuric chloride, triethylamine as base, and anhydrous acetonitrile as solvent at room temperature gives the corresponding sulfonamides in good to excellent yields. Georg Thieme Verlag Stuttgart.

Cinnoline compounds

The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3aklylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.